1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines - Aiming for Global Disease Prevention
2.2 What is the Social and Economic Burden?
2.3 Vaccine Technology
2.3.1 Inactivated Vaccines
2.3.2 Live Attenuated Vaccines
2.3.3 Conjugate Vaccines
2.3.4 Recombinant Vector Vaccines
2.4 Key Influencers of the Human Vaccine Market
2.4.1 Governments and International Organizations
2.4.1.1 The World Health Organisation (WHO)
2.4.1.2 The Governmental Influence
2.4.2 Leading Manufacturers
2.4.2.1 Merck& Co.
2.4.2.2 Sanofi
2.4.2.3 GlaxoSmithKline
2.4.2.4 Pfizer
2.5 Human World Vaccines - Market Segmentation
2.5.1 Paediatric Vaccines
2.5.2 Adult Vaccines
2.5.3 Elderly Vaccines
2.5.4 Travel Vaccines
2.5.5Therapeutic Vaccines
3. World Vaccine Market Outlook, 2017-2028
3.1 World Vaccine Market, 2017
3.1.1 Paediatric Vaccines Maintains Constant Demand
3.1.2 Ageing Population Requires More Care
3.1.3 Emerging Markets Demand Better Immunity
3.2 The World Human Vaccines Forecast, 2017-2028
3.3The World Vaccine Market: Industry Trends, 2017-2028
3.3.1 Undulating Demand
3.3.2 Supply Restraints
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy
4. World Vaccine Submarkets: Prospects, 2017-2028
4.1 Paediatric Vaccines
4.1.1 Paediatric Vaccine Forecast, 2017-2028
4.1.2 Paediatric Vaccine Trends
4.1.2.1 Innovative Delivery
4.1.2.2 Fear Factor
4.1.2.3 Novel Vectors
4.2 Adult Vaccines
4.2.1 Adult Vaccine Forecast, 2017-2028
4.2.2 Adult Vaccine Trends
4.2.2.1 Fighting the Flu
4.2.2.2 HPV
4.2.2.3 Repeat Doses for Continued Protection
4.3 Elderly Vaccines
4.3.1 Elderly Vaccine Forecast, 2017-2028
4.3.2 Elderly Vaccine Trends
4.3.2.1 With Age Comes Greater Risk
4.3.2.2 Ageing Population across the Globe
4.4 Travel Vaccines
4.4.1 Travel Vaccines Forecast, 2017-2028
4.4.2 Travel Vaccine Trends
4.4.2.1 Zika Virus Outbreak
4.4.2.2 Globalization Carries Diseases
4.5 Therapeutic Vaccines
4.5.1 Therapeutic Vaccine Trends
5. Leading Vaccines: Revenue Forecasts, 2017-2028
5.1 Prevnar (Pfizer) - Pneumococcal Pneumonia
5.2 Gardasil (Merck and Co.) - HPV
5.3 Fluzone (Sanofi) - Influenza
5.4 Pentacel (Sanofi) - DtaP, Polio, HiB
5.5 ProQuad / M-M-R II / Varivax (Merck and Co.) - Varicella/Chickenpox, Measles, Mumps, Rubella.
5.6 Infanrix/Pediarix (GSK) - Diptheria, Tetanus and Acellular Pertussis
5.7 Zostavax (Merk and Co.) - Herpes
5.8 RotaTeq (Merck and Co.) - Rotavirus
5.9 Hepatitis Vaccines (GSK) - Hepatitis A & B
5.10 Menactra (Sanofi) - Meningococcal
6. Leading Developed National Vaccines Markets, 2017-2028
6.1 The United States Vaccine Market, 2017-2028
6.1.1 The US Vaccine Market, 2017
6.1.2 The US Vaccine Market Forecast, 2017-2028
6.2 Japanese Vaccine Market, 2017-2028
6.2.1 The Japanese Vaccine Market, 2017
6.2.2 The Japanese Vaccine Market Forecast, 2017-2028
6.2.3 Addressing the Alleged Vaccine Gap
6.3 EU5Vaccine Market, 2017-2028
6.3.1 The EU5 Vaccine Market, 2017
6.3.2 The EU5 Vaccine Market Forecast, 2017-2028
6.4 United Kingdom Vaccine Market, 2017-2028
6.4.1 The UK Vaccine Market, 2018
6.4.2 The UK Vaccine Market Forecast, 2017-2028
6.5 France: Vaccine Market, 2017-2028
6.5.1 The French Vaccine Market, 2017
6.5.2 The French Vaccine Market Forecast, 2017-2028
6.5.3 French Healthcare System - Immunization Policy
6.6 Germany: Vaccine Market, 2017-2028
6.6.1 The German Vaccine Market, 2017
6.6.2 The German Vaccine Market Forecast, 2017-2028
6.7 Italy: Vaccine Market, 2017-2028
6.7.1 The Italian Vaccine Market, 2017
6.7.2 The Italian Vaccine Market Forecast, 2017-2028
6.7.3 Challenges in Public Healthcare
6.8 Spain: Vaccine Market, 2017-2028
6.8.1 The Spanish Vaccine Market, 2017
6.8.2 The Spanish Vaccine Market Forecast, 2017-2028
6.8.3 District Rules - Economic Challenges
7. Leading Emerging National Markets, 2017-2028
7.1 China: Vaccine Market, 2017-2028
7.1.1 The Chinese Vaccine Market, 2017
7.1.2 The Chinese Vaccine Market Forecast, 2017-2028
7.1.3 Setting-Up Domestic Vaccine Industries
7.2 India: Vaccine Market, 2017-2028
7.2.1 The Indian Vaccine Market, 2017
7.2.2 The Indian Vaccine Market Forecast, 2017-2028
7.2.3 The Extent to which the Vaccine Market Can Flourish?
7.3 Brazil: Vaccine Market, 2017-2028
7.3.1 The Brazilian Vaccine Market, 2017
7.3.2 The Brazilian Vaccine Market Forecast, 2017-2028
7.3.3 Zika Outbreak
7.4 Russia: Vaccine Market, 2017-2028
7.4.1 The Russian Vaccine Market, 2017
7.4.2 The Russian Vaccine Market Forecast, 2017-2028
7.4.3 Power of the State
8. Leading Manufacturers of Vaccines for Human Use 2018
8.1 GlaxoSmithKline (GSK)
8.1.1 GSK Vaccine Performance
8.1.2 GSK Developments
8.1.2.1 Mergers and Acquisitions
8.1.2.2 GSK Vaccine Pipeline
8.2 Merck& Co.
8.2.1 Merck Vaccine Performance
8.2.2 Merck Developments
8.2.2.1 Merck Market Movements
8.2.2.2 Collaborations
8.2.2.3 Merck Pipeline
8.3 Sanofi
8.3.1 Sanofi Vaccine Performance
8.3.2 Sanofi Developments
8.3.2.1 Acquisitions & Expansions
8.3.2.2 Sanofi Vaccine Pipeline
8.4 Pfizer
8.4.1 Pfizer Vaccine Performance
8.4.2 Pfizer Developments
8.4.2.1 Pfizer Mergers & Acquisitions
8.4.2.2 Pfizer Pipeline
8.5 Johnson & Johnson
8.6 AstraZeneca
8.7 Other Companies Serving the Vaccines Market
9. Research & Development, 2018
9.1 Prophylactic Vaccines R&D Pipeline
9.1.1 Paediatric Vaccines R&D Pipeline
9.1.2 Adult Vaccines R&D Pipeline
9.1.3 Elderly Vaccines R&D Pipeline
9.1.4 Travel Vaccines R&D Pipeline
9.2 Therapeutic Vaccines R&D Pipeline
10. Qualitative Analysis of the World Vaccines Market, 2017-2028
10.1 SWOT Analysis of the World Human Vaccines Market, 2017
10.1.1 Strengths
10.1.1.1 Ageing Population
10.1.1.2 Prevention is Better than Cure
10.1.1.3 Demand from Emerging Markets Continue
10.1.1.4 Promising R&D Pipeline
10.1.1.5 Increasing Awareness
10.1.2 Weaknesses
10.1.2.1 High Manufacturing Costs
10.1.2.2 Time Constraints
10.1.2.3 Barriers to Market Entry
10.1.3 Opportunities
10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
10.1.3.2 Shifting Focus on Adults Vaccines
10.1.4 Threats
10.1.4.1 Oligarchic Presence of Pharmaceutical Giants
10.1.4.2 Productivity Gap
10.2 STEP Analysis of the World Human Vaccines Industry and Market, 2017-2028
10.2.1 Social Factors
10.2.1.1 Maintaining a Healthier Workforce
10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects
10.2.2 Technological Forces
10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
10.2.3 Economic Factors
10.2.3.1 High Costs of Production
10.2.3.2 Soaring Vaccines Demand from Developing Countries
10.2.4 Political Factors
10.2.4.1 Governments Play Crucial Roles in Vaccination
11. Conclusions
11.1 Segment Market Share Shift
11.2 Elderly People Become the New Target Market
11.3 Endemic Infections Drive Travel Vaccines Growth
11.4 Emerging Markets: High Demand for Vaccines
11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
11.6 Strong and Diverse Research and Development
11.7 Concluding Remarks
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
Table of Tables
Table 1.1 Selected National Vaccines Markets: Revenues ($bn) and Market Shares (%) by Leading Country, 2017, 2022 and 2028 (Sample)
Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2017-2028
Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn),2017-2028
Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2028
Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.1 Prevnar Revenue ($bn), 2014-2017
Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.3 Gardasil Revenue ($bn), 2014-2017
Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2016
Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.7 Pentacel Revenue ($bn), 2014-2016
Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2013-2016
Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016
Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.13 Zostavax Revenue ($bn), 2013-2016
Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.15 RotaTeq Revenue ($bn), 2013-2016
Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016
Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 5.19 Menactra Revenue ($bn), 2014-2016
Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.1 Leading National Market Revenue Forecasts($bn), 2017, 2022, 2028
Table 6.2 Leading Developed National Markets Revenue Forecasts($bn), 2017, 2022, 2028
Table 6.3 Leading Developed National Market Shares (%), 2017, 2022, 2028
Table 6.4 The US Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.5 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.6 The EU5 Vaccines World Market Shares (%), 2017, 2022, 2028
Table 6.7 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.8 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.9 The French Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.10 The German Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.11 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 6.12 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 7.1 Leading Emerging National Market Revenue Forecasts($bn), 2017, 2022, 2028
Table 7.2 Leading Emerging National Market Shares (%), 2017, 2022, 2028
Table 7.3 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 7.4 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 7.5 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 7.6 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2028
Table 8.1 GSK Geographic Revenue ($bn), 2016
Table 9.1 Prophylactic Vaccines in Development, 2017
Table 9.2 Paediatric Vaccines in Development, 2017
Table 9.3 Adult Vaccines in Development, 2017
Table 9.4 Elderly Vaccines in Development, 2017
Table 9.5 Travel Vaccines in Development, 2017
Table 9.6 Therapeutic Vaccines in Development, 2017
Table of Figures
Figure 1.1 World Vaccines Market Segmentation, 2017
Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2017
Figure 3.2 World Vaccines Leading National Market Shares (%), 2017
Figure 3.3 World Vaccines Leading National Market Shares (%), 2022
Figure 3.4 World Vaccines Leading National Market Shares (%), 2028
Figure 3.5 World Vaccines Market: Drivers and Restraints, 2017-2028
Figure 4.1 World Prophylactic Vaccines Submarket (%) Segmentation, 2018
Figure 4.2 World Paediatric Vaccines Market Share (%), 2018
Figure 4.3 World Paediatric Vaccines Market Share (%), 2022
Figure 4.4 World Paediatric Vaccines Market Share (%), 2028
Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2017-2028
Figure 4.6 World Adult Vaccines Market Share (%), 2018
Figure 4.7 World Adult Vaccines Market Share(%), 2022
Figure 4.8 World Adult Vaccines Market Share(%), 2028
Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2017-2028
Figure 4.10 World Elderly Vaccines Market Share (%), 2018
Figure 4.11 World Elderly Vaccines Market Share (%), 2022
Figure 4.12 World Elderly Vaccines Market Share (%), 2028
Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2017-2028
Figure 4.14 World Travel Vaccines Market Share (%), 2018
Figure 4.15 World Travel Vaccines Market Share (%), 2022
Figure 4.16 World Travel Vaccines Market Share (%), 2028
Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2017-2028
Figure 5.1 Prevnar Revenue Forecast ($bn), 2017-2028
Figure 5.2 Gardasil Revenue Forecast ($bn), 2017-2028
Figure 5.3 Fluzone Revenue Forecast ($bn), 2017-2028
Figure 5.4 Pentacel Revenue Forecast ($bn), 2017-2028
Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2017-2028
Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2017-2028
Figure 5.7 Zostavax Revenue Forecast ($bn), 2017-2028
Figure 5.8 RotaTeq Revenue Forecast ($bn), 2017-2028
Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2017-2028
Figure 5.10 Menactra Revenue Forecast ($bn), 2017-2028
Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.3 EU5 Vaccines Market Share (%), 2017
Figure 6.4 EU5 Vaccines Market Share (%), 2022
Figure 6.5 EU5 Vaccines Market Share(%), 2028
Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2017-2028
Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2017-2028
Figure 7.1 BRIC Countries Vaccines Market Share (%), 2017
Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2022
Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2028
Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2017-2028
Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2017-2028
Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2017-2028
Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2017-2028
Figure 8.1 GSK Vaccines Revenue ($bn), 2014-2016
Figure 8.2 GSK Vaccines Region Breakdown (%), 2017
Figure 8.3 Merck Vaccines Revenue ($bn), 2014-2016
Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017
Figure 10.1 SWOT Analysis of the World Vaccines Market, 2017
Figure 10.2 STEP Analysis of the World Vaccines Market, 2017
